全面准入？市场准入与卫生技术评估进展综述：第8部分。
Access in all areas? A round up of developments in market access and health technology assessment: part 8.
作者信息
Ramagopalan Sreeram V, Pannelay Annie Jullien
机构信息
Centre for Pharmaceutical Medicine Research, King's College London, SE1 9NH, UK.
ProductLife Group, 10 avenue de l'arche, 92400 Courbevoie, France.
出版信息
J Comp Eff Res. 2025 Aug;14(8):e250091. doi: 10.57264/cer-2025-0091. Epub 2025 Jun 17.
Abstract
In this update, we discuss the pricing paradox of combination therapies in health technology assessment; examine the Inflation Reduction Act's impact on pharmaceutical innovation and analyze the revised Dutch economic evaluation guidelines.
摘要
在本次更新中，我们讨论了卫生技术评估中联合疗法的定价悖论；研究了《降低通胀法案》对药物创新的影响，并分析了荷兰修订后的经济评估指南。
相似文献
1
Access in all areas? A round up of developments in market access and health technology assessment: part 8.全面准入？市场准入与卫生技术评估进展综述：第8部分。
J Comp Eff Res. 2025 Aug;14(8):e250091. doi: 10.57264/cer-2025-0091. Epub 2025 Jun 17.
2
Access in all areas? A round up of developments in market access and health technology assessment: part 7.全面准入？市场准入与卫生技术评估发展综述：第7部分。
J Comp Eff Res. 2025 Jun;14(6):e250043. doi: 10.57264/cer-2025-0043. Epub 2025 Apr 14.
3
Access in all areas? a round up of developments in market access and health technology assessment: part 4.所有领域都能准入吗？市场准入和卫生技术评估发展情况综述：第 4 部分。
J Comp Eff Res. 2024 Jun;13(6):e240060. doi: 10.57264/cer-2024-0060. Epub 2024 Apr 22.
4
A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key Stakeholders.国际药品价格谈判框架的比较分析：关键利益相关者访谈研究
Milbank Q. 2024 Dec;102(4):1004-1031. doi: 10.1111/1468-0009.12714. Epub 2024 Sep 17.
5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 19.我们准备好申请报销了吗？与卫生技术评估相关的真实世界证据发展综述：第19部分。
J Comp Eff Res. 2025 Jul;14(7):e250063. doi: 10.57264/cer-2025-0063. Epub 2025 May 12.
6
Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch.为美国医疗保险药品价格谈判提供信息：阿哌沙班和利伐沙班上市多年后的价值评估方法学考虑。
Value Health. 2024 Nov;27(11):1507-1514. doi: 10.1016/j.jval.2024.07.011. Epub 2024 Jul 31.
7
The New Dutch Guideline for Economic Evaluations in Healthcare: Taking the Societal Perspective to the Next Level.《荷兰医疗保健经济评估新指南：将社会视角提升到新高度》
Value Health. 2025 Jun;28(6):930-935. doi: 10.1016/j.jval.2025.03.002. Epub 2025 Mar 20.
8
Applying early health technology assessment (e-HTA) to inform investment in novel health technologies in the US.应用早期卫生技术评估（e-HTA）为美国新型卫生技术的投资提供信息。
Int J Technol Assess Health Care. 2025 Jul 8;41(1):e45. doi: 10.1017/S0266462325100275.
9
Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.药品政策：参考定价、其他定价及采购政策的影响
Cochrane Database Syst Rev. 2014 Oct 16;2014(10):CD005979. doi: 10.1002/14651858.CD005979.pub2.
10
Digital interventions in mental health: evidence syntheses and economic modelling.数字干预在精神健康中的应用：证据综合和经济建模。
Health Technol Assess. 2022 Jan;26(1):1-182. doi: 10.3310/RCTI6942.
本文引用的文献
1
Pricing combination products: not how but who?组合产品定价：不是如何定价，而是由谁定价？
Eur J Health Econ. 2025 Jun;26(4):537-540. doi: 10.1007/s10198-025-01773-8. Epub 2025 Apr 17.
2
Access in all areas? A round up of developments in market access and health technology assessment: part 7.全面准入？市场准入与卫生技术评估发展综述：第7部分。
J Comp Eff Res. 2025 Jun;14(6):e250043. doi: 10.57264/cer-2025-0043. Epub 2025 Apr 14.
3
The Inflation Reduction Act's Impact Upon Early-Stage Venture Capital Investments.《降低通胀法案》对早期风险投资的影响。
Ther Innov Regul Sci. 2025 Jul;59(4):769-780. doi: 10.1007/s43441-025-00773-3. Epub 2025 Apr 13.
4
The need to consider market access for pharmaceutical investment decisions: a primer.制药投资决策中考虑市场准入的必要性：入门指南。
J Comp Eff Res. 2025 May;14(5):e250036. doi: 10.57264/cer-2025-0036. Epub 2025 Apr 4.
5
The New Dutch Guideline for Economic Evaluations in Healthcare: Taking the Societal Perspective to the Next Level.《荷兰医疗保健经济评估新指南：将社会视角提升到新高度》
Value Health. 2025 Jun;28(6):930-935. doi: 10.1016/j.jval.2025.03.002. Epub 2025 Mar 20.
6
An Attribution of Value Framework for Combination Treatments.联合治疗的价值归因框架
Value Health. 2025 Jan;28(1):72-80. doi: 10.1016/j.jval.2024.08.012. Epub 2024 Oct 29.
7
Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies.联合疗法基于总体结果的价值归因框架提案。
Value Health. 2025 Jan;28(1):81-87. doi: 10.1016/j.jval.2024.07.019. Epub 2024 Aug 9.
8
Access in all areas? A round up of developments in market access and health technology assessment: part 2.全覆盖？市场准入和卫生技术评估发展综述：第 2 部分。
J Comp Eff Res. 2023 Dec;12(12):e230162. doi: 10.57264/cer-2023-0162. Epub 2023 Nov 2.
9
Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop.肿瘤学中联合治疗方案的估值与支付挑战：多利益相关方国际研讨会观点汇报
BMC Health Serv Res. 2021 May 3;21(1):412. doi: 10.1186/s12913-021-06425-0.
Zotero 插件